Michael Panzara

Statistics

Publications

Citations

13.6K

H-Index

Active since

1992

Affiliations

Biogen (United States)(Current)

Cleveland Clinic

University College London

Wave Life Sciences (United States)

University of Pennsylvania

Michael Panzara is an author at Biogen (United States) specializing in multiple sclerosis, neurology, and relapsing-remitting multiple sclerosis treatment.

ORCID

Publications per year

1992–2021

Publications

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová et al. · New England Journal of Medicine · 2006 · 3.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold et al. · New England Journal of Medicine · 2008 · 2.4K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +15

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Richard A. Rudick, William H. Stuart, Peter A. Calabresi et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +11

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

Life Sciences, Immunology, Neurology +11

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

Life Sciences, Immunology, Neurology +11

1–5 of 39